Pembrolizumab-Induced Diabetes Mellitus Presenting as Diabetic Ketoacidosis in a Patient With Metastatic Colonic Adenocarcinoma

Pembrolizumab-Induced Diabetes Mellitus Presenting as Diabetic Ketoacidosis in a Patient With Metastatic Colonic Adenocarcinoma

Immunotherapy drugs are gaining popularity in the treatment of certain malignancies due to the success of these agents in recent clinical trials. Pembrolizumab is an immune checkpoint inhibitor that acts via binding to programmed cell death 1 (PD-1) receptors on T-cells, allowing for the constitutiv...

Full description

Bibliographic Details
Main Authors: Asim Kichloo MD, Michael S. Albosta MD, Shane McMahon MD, Kimberly Movsesian MD, Farah Wani MD, Shakeel M. Jamal MD, Michael Aljadah MD, Jagmeet Singh MD
Format: Article
Language:English
Published: SAGE Publishing 2020-08-01
Series:Journal of Investigative Medicine High Impact Case Reports
Online Access:https://doi.org/10.1177/2324709620951339

Internet

https://doi.org/10.1177/2324709620951339

Similar Items